Browse Studies — Arctuva

Phase 1

A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE)

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic m…

Locally Advanced Solid TumorsMetastatic Solid TumorsLymphoma+1 more

Estimated

~$10 – $8,750

Turning Point Therapeutics, Inc.NCT04094610

Phase 1

A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).

The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targ…

Somatostatin Receptor PositiveNETsLymphoma+5 more

Estimated

~$10 – $8,750

ITM Solucin GmbHNCT06441331

Observational

Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors

Background: Primary central nervous system (CNS) tumors grow in the brain and spinal cord. These tumors are rare, but they are difficult to treat and often fa…

Recurrent CNS TumorsBrain CancerGliomas+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07374692

Phase 4

68Ga(Gallium)-DOTATATE Positron Emission Tomography (PET)/MRI in the Diagnosis and Management of Somatostatin Receptor Positive Central Nervous System CNS Tumors.

The study population consists of patients who undergo resection for somatostatin receptor-positive (SSTR-positive) CNS tumors, focusing on meningioma, and incl…

CNS TumorsMeningiomaEsthesioneuroblastoma+4 more

Estimated

~$10 – $6,250

Weill Medical College of Cornell UniversityNCT04081701